Results 1 to 10 of about 1,401 (145)

Patterns and predictors of therapeutic response to efgartigimod in acetylcholine receptor-antibody generalized myasthenia gravis subtypes [PDF]

Therapeutic Advances in Neurological Disorders
Background: Efgartigimod is an approved biologic for generalized myasthenia gravis (gMG), which is an autoimmune disease and can potentially be life-threatening. However, the therapeutic response to efgartigimod among the acetylcholine receptor gMG (AChR-
Zhang-Yu Zou, Qinzhou Wang, Jian-Quan Shi   +2 more
exaly   +4 more sources

Efgartigimod as a treatment for people with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): a plain language summary of publication of the ADHERE trial [PDF]

Therapeutic Advances in Neurological Disorders
Summary What is this summary about? This is a plain language summary of an article published in The Lancet Neurology in 2024. The article describes the results of the ADHERE clinical study, which involved people with chronic inflammatory demyelinating ...
Jeffrey A. Allen, Luis Querol, Niraja Suresh, Anneleen Remmerie, Trevor Mole, Kelly McCoy, Lisa Butler, Benjamin van Hoorick, Satoshi Kuwabara, Pieter A. van Doorn, Richard A. Lewis   +10 more
doaj   +2 more sources

Real-world outcomes after switching from standard therapy to efgartigimod in five patients with chronic inflammatory demyelinating polyradiculoneuropathy: a case series study in Japan [PDF]

Frontiers in Neurology
BackgroundEfgartigimod, a neonatal Fc receptor blocker, has received regulatory approval for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) in Japan in December 2024.AimsTo investigate the effectiveness and safety of ...
Tatsuya Imai, Kenichi Irie, Shinichiro Mori, Tomoaki Hoshino, Toshihiro Ide, Takahisa Tateishi   +5 more
doaj   +2 more sources

Case report: Efgartigimod treatment in two pediatric patients with chronic inflammatory demyelinating polyneuropathy [PDF]

Frontiers in Immunology
BackgroundChronic inflammatory demyelinating polyneuropathy (CIDP) is the most common chronic immune-mediated polyneuropathy. Early and effective immunomodulatory treatment is essential to prevent long-term disability.
Yanping Ran, Wenlin Wu, Chi Hou, Haixia Zhu, Wenxiao Wu, Zongzong Chen, Xuexia Ma, Xiaolan Mo, Houliang Deng, Yuanyuan Gao, Xiaojing Li   +10 more
doaj   +2 more sources

Add-on efgartigimod in myasthenic crisis: a promising treatment option [PDF]

Frontiers in Neurology
BackgroundIn myasthenia crisis (MC), plasma exchange (PE) and intravenous immunoglobulin (IVIG) are confirmed effective treatment options, but PE may not be available in time, and the response rate to IVIG is not always satisfactory.
Fangyi Shi, Fangyi Shi, Fangyi Shi, Jing Wang, Jing Wang, Jing Wang, Jiaxin Chen, Jiaxin Chen, Jiaxin Chen, Rong Lai, Rong Lai, Rong Lai, Li Feng, Li Feng, Li Feng, Hongyan Zhou, Hongyan Zhou, Hongyan Zhou, Xunsha Sun, Xunsha Sun, Xunsha Sun, Cunzhou Shen, Cunzhou Shen, Cunzhou Shen, Jiezhen Feng, Jiezhen Feng, Jiezhen Feng, Xin Huang, Xin Huang, Xin Huang, Huiyu Feng, Huiyu Feng, Huiyu Feng, Haiyan Wang, Haiyan Wang, Haiyan Wang   +35 more
doaj   +2 more sources

Efgartigimod versus intravenous immunoglobulin in the treatment of patients with impending myasthenic crisis

Scientific Reports
Impending myasthenic crisis (IMC) is an emergent situation requiring aggressive management to prevent patients from developing myasthenic crisis (MC) in patients with myasthenia gravis (MG).
Huiqiu Zhang, Xiaomin Pang, Rongjuan Zhao   +2 more
exaly   +2 more sources

Case Report: A myasthenia gravis patient complicated with renal failure was effectively treated with efgartigimod [PDF]

Frontiers in Immunology
Myasthenia gravis (MG) is a neuromuscular junction disorder clinically characterized by fluctuating muscle weakness, in which some patients with respiratory muscle weakness are at risk of progressing to myasthenia gravis crisis and respiratory failure ...
Jia Ke, Qi Zhao, Na Wang, Bei Zhang, Jin-Quan Hu   +4 more
doaj   +3 more sources

Efgartigimod combined with rituximab helps improve the symptoms and reduce the use of corticosteroids in patients with MuSK antibody-positive MG: a single case report [PDF]

Frontiers in Immunology
IntroductionMyasthenia gravis (MG) is an autoimmune disorder primarily affecting the neuromuscular junction. Muscle-specific receptor tyrosine kinase antibody (MuSK-Ab)-mediated MG often presents with bulbar weakness and is prone to crisis.
Xiujun Zheng, Jing Wang, Tongtong Cai, Houshi Zhou   +3 more
doaj   +2 more sources

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): A Comprehensive Review of Types, Pathophysiology, and Treatment Approaches [PDF]

Brain and Behavior
Purpose of Review: This review aims to provide a comprehensive analysis of chronic inflammatory demyelinating polyneuropathy (CIDP), focusing on its clinical manifestations, pathophysiology, and treatment advancements, with particular emphasis on ...
Ayesha Khan, Arsal Khan, Kuldeep Dalpat Rai, Anzel Saeed, Harsh Kumar, Aneesh Kumar Sangtiani, Tehreem Fatima, Muhammad Tanveer Alam, Faiza Rajput, Sakshi Chawla, Hussain Haider Shah, Humaira Kalam   +11 more
doaj   +2 more sources

Efficacy and safety of efgartigimod in very-late-onset myasthenia gravis [PDF]

Frontiers in Immunology
BackgroundMyasthenia gravis (MG) is an autoimmune disease. Recently, the prevalence of very late-onset MG (VLOMG; onset ≥ 65 years) has rapidly increased.
Yunbin Zhao, Meijie Qu, Xi Rong, Xupeng Sun, Li Wang, Min Liu, Jiaona Sui   +6 more
doaj   +2 more sources